Report: ‘Authorized generics’ contribute to market distortion


'Authorized generics' contribute to market distortion, report says A new report from the Federal Trade Commission has said "authorized generics" lead to pharmaceutical companies striking deals at the expense of patients.

An authorized generic exists when a pharmaceutical manufacturer sells a drug under both a brand-name and generic label, and the commission says it has become increasingly common for brand-name drug makers to begin marketing authorized generics at the same time the generic firm is beginning its 180-day marketing exclusivity period.

Authorized Generics: An Interim Report has found that drug prices are on average 4.2 percent lower when authorized generics are marketed against a generic drug.

Their introduction also substantially reduces the revenues of a first-filer generic firm, with declines ranging from 47 to 51 percent. As a result, some generic firms are willing to agree to defer their market entry in return for a brand’s promise not to launch an authorized generic during the marketing exclusivity period.

The report concludes that such deals can harm consumers by making the drugs available in the branded-only version for longer.

Consumers may also lose the benefit of price discounts from authorized generic competition during the 180-day marketing exclusivity period, because the brand has agreed not to compete against the generic drug during that time.

Personal Liberty

Personal Liberty News Desk

Join the Discussion

Comment Policy: We encourage an open discussion with a wide range of viewpoints, even extreme ones, but we will not tolerate racism, profanity or slanderous comments toward the author(s) or comment participants. Make your case passionately, but civilly. Please don't stoop to name calling. We use filters for spam protection. If your comment does not appear, it is likely because it violates the above policy or contains links or language typical of spam. We reserve the right to remove comments at our discretion.